Vemurafenib-induced granulomatous hepatitis

Erin K. Spengler; David E. Kleiner; Robert J. Fontana

doi:10.1002/hep.28692

Vemurafenib-induced granulomatous hepatitis

Erin K. Spengler, David E. Kleiner, Robert J. Fontana

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Vemurafenib (Zelboraf; Genentech, CA) is a highly effective oral chemotherapy agent for patients with metastatic melanoma who carry the BRAF V600E mutation. Side effects of this protein kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up to one third of treated patients. Mild abnormalities in liver biochemistries were reported with vemurafenib use in 30% of subjects, 11% developed severe laboratory abnormalities, and acute liver failure has been reported (Table). Herein, a case of severe vemurafenib-induced granulomatous hepatitis leading to chronic cholestasis is reported along with a review of the hepatotoxicity of other PKIs.

Original language	English (US)
Pages (from-to)	745-748
Number of pages	4
Journal	Hepatology
Volume	65
Issue number	2
DOIs	https://doi.org/10.1002/hep.28692
State	Published - Feb 1 2017
Externally published	Yes

ASJC Scopus subject areas

Hepatology

Access to Document

10.1002/hep.28692

Cite this

@article{66c00c05777248d0b941563ba41c29c8,

title = "Vemurafenib-induced granulomatous hepatitis",

abstract = "Vemurafenib (Zelboraf; Genentech, CA) is a highly effective oral chemotherapy agent for patients with metastatic melanoma who carry the BRAF V600E mutation. Side effects of this protein kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up to one third of treated patients. Mild abnormalities in liver biochemistries were reported with vemurafenib use in 30% of subjects, 11% developed severe laboratory abnormalities, and acute liver failure has been reported (Table). Herein, a case of severe vemurafenib-induced granulomatous hepatitis leading to chronic cholestasis is reported along with a review of the hepatotoxicity of other PKIs.",

author = "Spengler, {Erin K.} and Kleiner, {David E.} and Fontana, {Robert J.}",

note = "Publisher Copyright: {\textcopyright} 2016 by the American Association for the Study of Liver Diseases",

year = "2017",

month = feb,

day = "1",

doi = "10.1002/hep.28692",

language = "English (US)",

volume = "65",

pages = "745--748",

journal = "Hepatology",

issn = "0270-9139",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Vemurafenib-induced granulomatous hepatitis

AU - Spengler, Erin K.

AU - Kleiner, David E.

AU - Fontana, Robert J.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Vemurafenib (Zelboraf; Genentech, CA) is a highly effective oral chemotherapy agent for patients with metastatic melanoma who carry the BRAF V600E mutation. Side effects of this protein kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up to one third of treated patients. Mild abnormalities in liver biochemistries were reported with vemurafenib use in 30% of subjects, 11% developed severe laboratory abnormalities, and acute liver failure has been reported (Table). Herein, a case of severe vemurafenib-induced granulomatous hepatitis leading to chronic cholestasis is reported along with a review of the hepatotoxicity of other PKIs.

AB - Vemurafenib (Zelboraf; Genentech, CA) is a highly effective oral chemotherapy agent for patients with metastatic melanoma who carry the BRAF V600E mutation. Side effects of this protein kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up to one third of treated patients. Mild abnormalities in liver biochemistries were reported with vemurafenib use in 30% of subjects, 11% developed severe laboratory abnormalities, and acute liver failure has been reported (Table). Herein, a case of severe vemurafenib-induced granulomatous hepatitis leading to chronic cholestasis is reported along with a review of the hepatotoxicity of other PKIs.

UR - http://www.scopus.com/inward/record.url?scp=84979790762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979790762&partnerID=8YFLogxK

U2 - 10.1002/hep.28692

DO - 10.1002/hep.28692

M3 - Article

C2 - 27335285

AN - SCOPUS:84979790762

SN - 0270-9139

VL - 65

SP - 745

EP - 748

JO - Hepatology

JF - Hepatology

IS - 2

ER -

Vemurafenib-induced granulomatous hepatitis

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this